주식/증권
📉 부정적
Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.
요약
Sarepta Therapeutics is seeing lower demand for its flagship gene therapy, Elevidys, following a regulatory crackdown.